Liver Diseases  >>  lomibuvir (VX 222)  >>  Phase 2
Welcome,         Profile    Billing    Logout  

3 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
lomibuvir (VX 222) / Trek Therapeutics
NCT01581138: VX-222 + Telaprevir + Ribavirin for 12 or 16 Weeks in Treatment-Naive Subjects With Genotype 1a Hepatitis C

Completed
2b
64
US
VX-222, telaprevir, VX-950, INCIVEK, INCIVO, TELAVIC, ribavirin, Copegus
Vertex Pharmaceuticals Incorporated
Chronic Hepatitis C Virus
06/13
12/13
NCT01516918 / 2011-004150-26: A Study to Evaluate the Efficacy and Safety of Quadruple Therapy (VX-222, Telaprevir,Peginterferon-Alfa-2a, Ribavirin) in Subjects With Chronic Hepatitis C With Compensated Cirrhosis

Completed
2b
103
US, Canada, Europe
VX-222, telaprevir, Incivek, VX-950, Incivo, ribavirin, Copegus, peginterferon-alfa-2a, Pegasys
Vertex Pharmaceuticals Incorporated
Chronic Hepatitis C Virus
09/13
12/13
NCT00911963: Pharmacokinetics of Multiple Ascending Doses of VCH-222 in Subjects With Chronic Hepatitis C Infection

Completed
1/2
49
US, Canada, RoW
VCH-222 or matching placebo, VCH-222 is also known as VX-222, peginterferon alfa-2a, ribavirin
Vertex Pharmaceuticals Incorporated, ViroChem Pharma
Hepatitis C
09/12
09/12

Download Options